| Tran, Huyen |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
| Recruiting | 2 | 12 | Europe, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia B with Inhibitor, Hemophilia B | 09/25 | 10/25 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 03/26 | 06/26 | | |
| Completed | 1/2 | 25 | Canada, US, RoW | SPK-8011 | Spark Therapeutics, Inc. | Hemophilia A | 12/23 | 12/23 | | |
| Young, Alan C |
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment |
|
|
| Recruiting | N/A | 122 | US | Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions | BrainQ Technologies Ltd. | Ischemic Stroke | 07/26 | 10/26 | | |
| Button, Brenda B |
| Recruiting | N/A | 30 | RoW | A-STEP, Alfred Step Test Exercise Protocol (A-STEP), A-STEP (New Protocol), Alfred Step Test Exercise Protocol, Comparator: CPET cycle ergometer (Gold Standard), Cardiopulmonary Exercise Test Protocol | The Alfred, Monash University | Cystic Fibrosis, Fibrosis, Lung Diseases, Respiratory Diseases, Genetic Diseases, Pancreatic Diseases | 07/24 | 10/24 | | |
| Snell, Greg I |
TFF-T2-001, NCT05501574: An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients |
|
|
| Terminated | 2 | 14 | RoW | Tacrolimus Inhalation Powder, Tacrolimus, Plastiape RS00 Dry Powder inhaler device | TFF Pharmaceuticals, Inc., Novotech (Australia) Pty Limited | Lung Transplant Rejection | 10/24 | 12/24 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | Lung transplant biopsy bites. | University of Alberta | Lung Transplant Rejection | 11/25 | 06/26 | | |
| Recruiting | N/A | 600 | Europe, Canada, US, RoW | | University of Alberta, Natera, Inc., One Lambda | Lung Transplantation | 11/26 | 12/27 | | |
| Holland, Anne E |
| Completed | N/A | 116 | RoW | Ambulatory Oxygen Therapy, Sham Ambulatory Oxygen Therapy | Monash University | Fibrotic Interstitial Lung Disease | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 131 | RoW | High intensity interval training, Traditional pulmonary rehabilitation | Monash University | Fibrotic Interstitial Lung Disease | 04/24 | 12/24 | | |
| Recruiting | N/A | 490 | RoW | Choice of home-based or centre-based pulmonary rehabilitation, Centre-based pulmonary rehabilitation | Monash University, Institute for Breathing and Sleep, Australia, University of Melbourne, La Trobe University, Thoracic Society of Australia and New Zealand, Lung Foundation Australia | Chronic Obstructive Pulmonary Disease | 12/24 | 12/25 | | |
| Smith, Jessica R |
NCT05228184: Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) |
|
|
| Active, not recruiting | 4 | 126 | US | Tirosint®-SOL, levothyroxine sodium oral solution (liquid), Levothyroxine Sodium, levothyroxine sodium tablets | IBSA Institut Biochimique SA, Cromsource | Congenital Hypothyroidism | 04/25 | 04/25 | | |
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 20 | RoW | LM-302, Toripalimab, Tuoyi | LaNova Australia Pty Limited | Advanced Solid Tumor | 11/23 | 11/23 | | |
NCT05055778: Establishing the Effectiveness of Publicly Available Smoking Cessation Resource |
|
|
| Completed | N/A | 49 | US | SmokefreeTXT | University of Virginia | Smoking Cessation | 02/24 | 02/24 | | |
| Kaye, David |
NCT04566874: SPIRAâ„¢-A 3D and HCT/p DBM vs. Medtronic Divergentâ„¢-L/Perimeterâ„¢ and Recombinant BMP-2 |
|
|
| Recruiting | N/A | 100 | US | ALIF | Camber Spine Technologies | Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis, Scoliosis | 07/21 | 07/21 | | |
| Recruiting | N/A | 750 | Europe, Canada, US, RoW | Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) | Corvia Medical | Heart Failure, Heart Failure, Diastolic | 05/25 | 03/31 | | |
NCT01918215: Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction. |
|
|
| Active, not recruiting | N/A | 449 | Europe, RoW | ICD, ILR | Flinders University, South Australian Health and Medical Research Institute | Heart Failure, Left Ventricular Systolic Dysfunction | 08/25 | 08/25 | | |
| Udy, Andrew |
ACTRN12619001328167p: The BONANZA trial- a randomised controlled trial that is testing whether a management strategy guided by early brain tissue oxygen monitoring in patients in with severe traumatic brain injury improves long term neurological and functional outcomes. |
|
|
| Not yet recruiting | 3 | 860 | | | Australian and New Zealand Research Centre, School of Public Health and Preventive Medicine, Monash University, NHMRC | Severe traumatic brain injury | | | | |
ACTRN12619001328167: The BONANZA trial- a randomised controlled trial that is testing whether a management strategy guided by early brain tissue oxygen monitoring in patients in with severe traumatic brain injury improves long term neurological and functional outcomes. |
|
|
| Recruiting | 3 | 860 | | | Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, NHMRC, Belgian Health Care Knowledge Centre (INV21-1323), Irish Health Research Board, Health Research Council of New Zealand (HRC Ref 21/937) | Severe traumatic brain injury | | | | |
| Recruiting | 3 | 1000 | RoW | Vasopressor, Fluids | Australian and New Zealand Intensive Care Research Centre | Shock, Septic | 10/25 | 12/26 | | |
ACTRN12620001361998p: SODium BICarbonate for metabolic acidosis in the Intensive Care Unit: A pilot, multicentre, double-blind, placebo controlled randomized clinical trial |
|
|
| Not yet recruiting | 2 | 60 | | | Australian and New Zealand Intensive Care Research Centre, Australian and New Zealand Intensive Care Research Centre | Metabolic acidosis | | | | |
ACTRN12616000940471: A Phase II Feasibility study to determine the efficacy and dose-response of a single enteral dose of Ivabradine to reduce participant heart rate in patients admitted to the intensive care unit with sepsis and sinus tachycardia |
|
|
| Recruiting | 2 | 20 | | | A/Prof Andrew Udy,, The Alfred Research Trust: Alfred Small Projects Grants | Sepsis, tachycardia | | | | |
ACTRN12620001361998: SODium BICarbonate for metabolic acidosis in the Intensive Care Unit: A pilot, multicentre, randomized, double-blind clinical trial |
|
|
| Terminated | 2 | 60 | | | Australian and New Zealand Intensive Care Research Centre, Australian and New Zealand Intensive Care Research Centre | Metabolic acidosis | | | | |
ACTRN12618000199213: Paramedic administered antibiotics for patients with severe sepsis: Does this reduce the time to appropriate antibiotic therapy? |
|
|
| Terminated | 2 | 110 | | | Ambulance Victoria, Ambulance Victoria | Sepsis | | | | |
| Not yet recruiting | 2 | 524 | NA | Fludrocortisone, Flurinef, Placebo | The George Institute | Aneurysmal Subarachnoid Hemorrhage | 07/29 | 07/30 | | |
| Completed | N/A | 21 | RoW | Supplemental parenteral nutrition | Australian and New Zealand Intensive Care Research Centre | Critically Ill | 02/23 | 02/23 | | |
NCT05542966: Blender Biomarkers: A BLENDER Sub-study to Evaluate the Effect of Oxygen Dose on Oxidative Stress and Organ Injury |
|
|
| Active, not recruiting | N/A | 30 | RoW | | Australian and New Zealand Intensive Care Research Centre | Cardiac Failure, Critical Illness | 08/23 | 12/23 | | |
NCT05855252: PRECISION-TBI - An Observational Study of Patients With Moderate to Severe Traumatic Brain Injury |
|
|
| Recruiting | N/A | 300 | RoW | No intervention | Australian and New Zealand Intensive Care Research Centre | Trauma, Brain | 04/25 | 07/25 | | |
REDEEM, NCT05562505: Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure |
|
|
| Recruiting | N/A | 140 | Europe, RoW | Venovenous ECMO | Australian and New Zealand Intensive Care Research Centre, The Alfred | Mechanical Ventilation Complication, Hypoxemia, Acute Respiratory Distress Syndrome Due to COVID-19, COVID-19 Respiratory Infection, Pneumonia, Extracorporeal Membrane Oxygenation | 07/26 | 01/27 | | |
| Recruiting | N/A | 80 | Europe, RoW | Blood sampling, Epithelial lining fluid sampling, Urine sampling, Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam | The University of Queensland, Royal Brisbane and Women's Hospital, The Alfred, University Hospital, Ghent, Centre Hospitalier Universitaire de Nīmes, Chinese University of Hong Kong, University of Malaya | Pneumonia | 12/21 | 12/21 | | |
| Ganju, Vinod |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma |
|
|
| Active, not recruiting | 3 | 214 | US, RoW | Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo | PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney | Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma | 06/25 | 02/26 | | |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 158 | RoW | LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane | Australasian Gastro-Intestinal Trials Group, University of Sydney | Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer | 06/25 | 10/25 | | |
| Recruiting | 2 | 160 | Europe, Canada, US, RoW | disitamab vedotin, RC48, RC48-ADC | Seagen Inc. | Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms | 05/26 | 05/28 | | |
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 64 | US, RoW | T3011, T3011 + pembrolizumab | ImmVira Pharma Co. Ltd | Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC | 10/23 | 10/25 | | |
NCT04565275: A Study of ICP-192 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 45 | US, RoW | Drug ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma | 11/23 | 04/24 | | |
EIK1003-001, NCT06253130: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 70 | US, RoW | IMP1734 | Eikon Therapeutics, Impact Therapeutics, Inc. | Advanced Solid Tumor | 02/26 | 12/26 | | |
NCT04618393: A Study of EMB-02 in Participants With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 47 | US, RoW | EMB-02 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumors | 07/23 | 03/24 | | |
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 20 | RoW | LM-302, Toripalimab, Tuoyi | LaNova Australia Pty Limited | Advanced Solid Tumor | 11/23 | 11/23 | | |
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors |
|
|
| Recruiting | 1/2 | 198 | Europe, Canada, US, RoW | disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380 | Seagen Inc., RemeGen Co., Ltd. | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 01/30 | 01/30 | | |
AK104-212, NCT05505825: A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 36 | RoW | AK104 IV infusion；Chiauranib oral | Akeso, Chipscreen Biosciences, Ltd. | SCLC,Extensive Stage | 12/24 | 01/25 | | |
NCT04814875: A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy |
|
|
| Terminated | 1/2 | 16 | RoW | ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD) | THERAPIM PTY LTD, Novotech (Australia) Pty Limited | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer | 11/23 | 11/23 | | |
SHR-A1904-I-104, NCT05277168: A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS |
|
|
| Recruiting | 1/2 | 83 | US, RoW | SHR-A1904 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 03/26 | 05/26 | | |
NCT05910827: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers |
|
|
| Recruiting | 1/2 | 98 | RoW | HMBD-001, Docetaxel, Cetuximab | Hummingbird Bioscience, Merck KGaA, Darmstadt, Germany | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma | 03/26 | 03/26 | | |
NCT04840784: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML |
|
|
| Terminated | 1a/1b | 9 | RoW | ETH-155008, study drug | Shengke Pharmaceuticals Pty Ltd | NHL, Leukemia | 05/23 | 05/23 | | |
| Terminated | 1 | 18 | RoW | LM-061, Kinase inhibitor, Toripalimab | LaNova Medicines Limited | Advanced Tumours | 07/22 | 12/22 | | |
| Recruiting | 1 | 35 | US, RoW | APG2575 | Ascentage Pharma Group Inc. | CLL/SLL | 03/25 | 06/26 | | |
| Recruiting | 1 | 24 | RoW | PTX-100 | Prescient Therapeutics, Ltd. | Advanced Cancer, PTCL | 04/23 | 04/23 | | |
| Completed | 1 | 26 | US, RoW | CI-8993 | Curis, Inc. | Solid Tumor | 05/23 | 05/23 | | |
| Active, not recruiting | 1 | 396 | US, RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd. | Advanced Solid Tumors | 12/25 | 03/26 | | |
NCT05198752: A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | Europe, RoW | Neoantigen mRNA Personalised Cancer SW1115C3 | Stemirna Therapeutics | Solid Tumor | 12/23 | 06/24 | | |
NCT05263180: A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. |
|
|
| Recruiting | 1 | 30 | RoW | EMB-09 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors |
|
|
| Completed | 1 | 6 | RoW | A:YH002+YH001, B:YH002+YH001, YH002+YH001 | Eucure (Beijing) Biopharma Co., Ltd | Advanced Solid Tumor | 07/23 | 07/23 | | |
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation |
|
|
| Terminated | 1 | 28 | Europe, RoW | BBP-398, sotorasib | Navire Pharma Inc., a BridgeBio company, Amgen | Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer | 08/24 | 08/24 | | |
| Recruiting | 1 | 18 | RoW | SR-8541A | Stingray Therapeutics | Advanced / Metastatic Solid Tumor | 08/24 | 08/24 | | |
NCT06007482: A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | ES009 | Elpiscience Biopharma Australia Pty. Ltd. | Advanced Solid Tumor | 08/24 | 08/25 | | |
NCT06730386: A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 100 | RoW | AK138D1 | Akeso | Solid Cancer | 02/28 | 08/28 | | |
NCT06560138: A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors |
|
|
| Withdrawn | 1 | 20 | RoW | SHR-4602 | Atridia Pty Ltd. | HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors | 12/25 | 09/26 | | |
NCT05872295: IKS014 in Advanced Solid Tumors That Express HER2 |
|
|
| Recruiting | 1 | 165 | RoW | IKS014 | Iksuda Therapeutics Ltd. | Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer | 09/25 | 09/27 | | |
| Recruiting | 1 | 102 | Europe, US, RoW | DF6215 | Dragonfly Therapeutics | Solid Tumor, Adult | 09/25 | 12/27 | | |
NCT06074497: This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors. |
|
|
| Recruiting | 1 | 54 | RoW | KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2, KGX101- Cohort 3, KGX101- Cohort 4, KGX101- Cohort 5, KGX101 and Envafolimab | Kangabio AUSTRALIA LTD PTY | Advanced or Metastatic Solid Tumors | 05/26 | 05/26 | | |
| Markman, Ben |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 20 | RoW | LM-302, Toripalimab, Tuoyi | LaNova Australia Pty Limited | Advanced Solid Tumor | 11/23 | 11/23 | | |
KEYNOTE-F49, NCT05763004: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 140 | RoW | IOS-1002, IOS-1002 + KEYTRUDA® (pembrolizumab) | ImmunOs Therapeutics AG, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 05/25 | 05/25 | | |
| Haydon, Andrew |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/26 | 08/29 | | |
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 64 | US, RoW | T3011, T3011 + pembrolizumab | ImmVira Pharma Co. Ltd | Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC | 10/23 | 10/25 | | |
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 159 | US, RoW | AU-007, Aldesleukin, Avelumab | Aulos Bioscience, Inc. | Advanced Solid Tumor, Metastatic Cancer | 08/25 | 09/25 | | |
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 258 | Europe, US, RoW | TAK-186, MVC-101 | Takeda | Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer | 09/25 | 11/26 | | |
| Recruiting | 1 | 35 | US, RoW | ACTM-838 | Actym Therapeutics, Inc. | Solid Tumor | 01/26 | 07/26 | | |
| Goh, Gerard |
| Recruiting | N/A | 30 | Europe, RoW | Alucent Vessel Restoration System for AVF | Alucent Biomedical | AV Fistula | 05/24 | 12/24 | | |
| Active, not recruiting | N/A | 50 | RoW | Vessel Restoration System (VRS) | Alucent Biomedical | PAD - Peripheral Arterial Disease | 11/27 | 11/27 | | |
| Active, not recruiting | N/A | 34 | RoW | BD™ Sirolimus Drug Coated Balloon Catheter percutaneous transluminal angioplasty | C. R. Bard | Peripheral Arterial Disease, Peripheral Artery Disease, Stenosis Artery | 06/24 | 12/25 | | |
CHAMPIONSHIP, NCT06410313: First in Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease And/or Proximal Popliteal Artery Disease |
|
|
| Recruiting | N/A | 30 | US, RoW | ChampioNIR Ridaforolimus Eluting Peripheral Stent System | Medinol Ltd. | Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis | 08/25 | 02/28 | | |
REACTIVATE I, NCT05455021: Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: |
|
|
| Active, not recruiting | N/A | 50 | RoW | Vessel Restoration System (VRS) | Alucent Biomedical | PAD - Peripheral Arterial Disease | 11/26 | 11/26 | | |
ACTRN12619000536167: Instylla Hydrogel Embolic System First In Human Study For Patients Requiring Vascular Embolization Alone or in the Pre-operative Setting for Treatment of Malignant and Benign Hypervascular Tumors, and Select Non-Traumatic End-Organ Infarct |
|
|
| Completed | N/A | 15 | | | Instylla Inc, Instylla Inc | Patients Requiring Vascular Embolization Alone for Treatment of Malignant Tumors, Patients Requiring Vascular Embolization in the Pre-operative Setting for Treatment of Malignant Tumors, Patients Requiring Vascular Embolization Alone for Treatment of Benign Hypervascular Tumors, Patients Requiring Vascular Embolization in the Pre-operative Setting for Treatment of Benign Hypervascular Tumors, Patients Requiring Vascular Embolization for Select Non-Traumatic End-Organ Infarct | | | | |
ACTRN12620000349943: Instylla Hydrogel Embolic System Pilot Study For Patients Requiring Transcatheter Embolization of Vascular Bleeds |
|
|
| Terminated | N/A | 15 | | | Instylla Inc, Instylla Inc | Patients Requiring Transcatheter Embolization of Vascular Bleeds | | | | |
| O'Brien, Terence |
NCT04714996: Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy |
|
|
| Recruiting | 2a | 24 | RoW | ES-481, Placebo, Open-Label Extension Study | ES Therapeutics Australia Pty Ltd | Drug Resistant Epilepsy | 12/23 | 12/23 | | |
NCT04153175: Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization |
|
|
| Terminated | 2 | 30 | RoW | ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC), Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC) | Cerebral Therapeutics LLC | Refractory Epilepsy | 03/24 | 03/24 | | |
NCT05518578: Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy |
|
|
| Recruiting | 2 | 35 | RoW | SPN-817, (-)-Huperzine A extended-release | Supernus Pharmaceuticals, Inc. | Epilepsy, Seizures, Epileptic | 10/24 | 01/25 | | |
| Recruiting | 2 | 20 | RoW | BMB-101 | Bright Minds Biosciences Pty Ltd | Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome | 09/25 | 10/25 | | |
NCT05947656: Evaluation of the NaviFUS System in Drug Resistant Epilepsy |
|
|
| Recruiting | N/A | 18 | RoW | NaviFUS System | Genovate-NaviFUS (Australia) Pty Ltd., Genovate Biotechnology Co., Ltd.,, NaviFUS Corporation | Epilepsy, Temporal Lobe, Drug Resistant Epilepsy | 05/25 | 05/25 | | |
| Wilson, John |
NCT01843504: Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy |
|
|
| Completed | 2 | 29 | US | platelet rich plasma, saline | University of Wisconsin, Madison | Chronic Patellar Tendinopathy, Chronic PT | 02/24 | 02/24 | | |
| Germaine, Jack |
NCT04153175: Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization |
|
|
| Terminated | 2 | 30 | RoW | ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC), Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC) | Cerebral Therapeutics LLC | Refractory Epilepsy | 03/24 | 03/24 | | |
NCT05518578: Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy |
|
|
| Recruiting | 2 | 35 | RoW | SPN-817, (-)-Huperzine A extended-release | Supernus Pharmaceuticals, Inc. | Epilepsy, Seizures, Epileptic | 10/24 | 01/25 | | |
NCT06466525: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. |
|
|
| Recruiting | 1 | 64 | RoW | LBT-3627, Placebo | Longevity Biotech Australia Pty Ltd (subsidiary) | Parkinson Disease | 03/25 | 03/25 | | |
| O'Brien, Terrence |
| Recruiting | 2 | 20 | RoW | BMB-101 | Bright Minds Biosciences Pty Ltd | Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome | 09/25 | 10/25 | | |
NCT05947656: Evaluation of the NaviFUS System in Drug Resistant Epilepsy |
|
|
| Recruiting | N/A | 18 | RoW | NaviFUS System | Genovate-NaviFUS (Australia) Pty Ltd., Genovate Biotechnology Co., Ltd.,, NaviFUS Corporation | Epilepsy, Temporal Lobe, Drug Resistant Epilepsy | 05/25 | 05/25 | | |
| Glaspole, Ian |
| Active, not recruiting | 3 | 597 | Europe, RoW | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 07/25 | 07/25 | | |
TELO-SCOPE, NCT04638517: The Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 50 | RoW | Danazol, Placebo | The University of Queensland | Pulmonary Fibrosis, Telomere Shortening, Telomere Disease, Dyskeratosis Congenita | 12/24 | 06/25 | | |
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease |
|
|
| Completed | 1/2 | 75 | RoW | LASN01, Placebo | Lassen Therapeutics 1 PTY LTD | Pulmonary Fibrosis, Thyroid Eye Disease | 11/24 | 11/24 | | |
NCT06122233: REBUILD-SM Study for People With Interstitial Lung Disease (ILD) |
|
|
| Recruiting | N/A | 400 | RoW | Pulmonary Fibrosis self-management package and smartphone application, REBUILD-SM | University of Sydney, Monash University, Lung Foundation Australia, University of Tasmania | Lung Diseases, Interstitial, Pulmonary Fibrosis | 06/27 | 08/27 | | |
| Frentzas, Sophia |
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 20 | RoW | LM-302, Toripalimab, Tuoyi | LaNova Australia Pty Limited | Advanced Solid Tumor | 11/23 | 11/23 | | |
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 159 | US, RoW | AU-007, Aldesleukin, Avelumab | Aulos Bioscience, Inc. | Advanced Solid Tumor, Metastatic Cancer | 08/25 | 09/25 | | |
| Recruiting | 1/2 | 182 | Europe, Canada, US, RoW | TAK-280 | Takeda, Takeda Development Center Americas, Inc. | Unresectable Locally Advanced or Metastatic Cancer | 02/25 | 07/26 | | |
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 258 | Europe, US, RoW | TAK-186, MVC-101 | Takeda | Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer | 09/25 | 11/26 | | |
| Recruiting | 1a/1b | 151 | RoW | AK112 | Akesobio Australia Pty Ltd | Neoplasms Malignant | 06/23 | 08/24 | | |
